Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single‐arm efficacy
Martin R. Wilkins(Hammersmith Hospital), Sofía S. Villar(MRC Biostatistics Unit), David G. Kiely(Royal Hallamshire Hospital), Stephen J. Wort(Royal Brompton Hospital), Jim Lordan(Freeman Hospital), Colin Church(Golden Jubilee National Hospital), Mark Toshner, JG Coghlan(Royal Free London NHS Foundation Trust), Martin Law(MRC Biostatistics Unit), Mikel A. McKie(Wellcome/MRC Cambridge Stem Cell Institute), Andreas–Antonios Roussakis(Hammersmith Hospital), Robin Condliffe(Royal Hallamshire Hospital), Lars Harbaum(Universität Hamburg), Luke Howard(Imperial College Healthcare NHS Trust), Jay Suntharalingam(Royal United Hospital Bath NHS Trust), Alexander Rothman(University of Minnesota)
Cited by 31
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k